

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purpose only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities of the Company.



HUAKANG BIOMEDICAL HOLDINGS COMPANY LIMITED

華康生物醫學控股有限公司

(Incorporated in Cayman Islands with limited liability)

(Stock Code: 8622)

SECOND SUPPLEMENTAL PLACING AGREEMENT IN RELATION TO PLACING OF NEW SHARES UNDER GENERAL MANDATE

Placing Agent



Reference is made to the announcement of Huakang Biomedical Holdings Company Limited (the “**Company**”) dated 20 June 2022 and the announcement of the Company issued earlier today and dated 7 July 2022 (the “**Announcements**”) in respect of the Placing. Unless defined otherwise, capitalised terms used herein shall have the same meanings as those defined in the Announcements.

SECOND SUPPLEMENTAL PLACING AGREEMENT

On 7 July 2022 (after trading hours of the Stock Exchange), the Company and the Placing Agent, after arm’s length negotiation, have entered into a second supplemental placing agreement (the “**Second Supplemental Placing Agreement**”), pursuant to which, the following changes have been made to the Placing Agreement:

1. Change of the Placing Price

The definition of the “Placing Price” in the Placing Agreement has been revised to not more than HK\$0.181 per Placing Share under the Second Supplemental Placing Agreement. Accordingly, the Placing Price for the Placing would be revised to not more than HK\$0.181 per Placing Share (the “**New Placing Price**”).

New Placing Price

The New Placing Price of not more than HK\$0.181 per Placing Share represents:

- (a) a discount of approximately 19.56% to the closing price of HK\$0.225 per Share as quoted on the Stock Exchange on 7 July 2022, being the date of the Second Supplemental Placing Agreement; and
- (b) a discount of approximately 19.91% to the average closing price per Share of approximately HK\$0.226 as quoted on the Stock Exchange for the last five consecutive trading days up to and including 6 July 2022, being the date immediately preceding the date of the Second Supplemental Placing Agreement.

The New Placing Price was determined and negotiated on an arm's length basis between the Company and the Placing Agent and with reference to the recent market price of the Shares. The Directors consider that the New Placing Price are fair and reasonable, and in the interests of the Company and the Shareholders as a whole.

2. Change of the Long Stop Date for the Placing Agreement

As additional time is required for fulfilment of the conditions under the Placing Agreement dated 20 June 2022, the Long Stop Date contemplated under the Placing Agreement has been extended from 8 July 2022 to 22 July 2022 (or such later date as may be agreed between the parties) under the Second Supplemental Placing Agreement.

EFFECTS OF THE AMENDMENTS UNDER THE SECOND SUPPLEMENTAL PLACING AGREEMENT

The Supplemental Placing Agreement is terminated and ceases to take effect upon the signing of the Second Supplemental Placing Agreement.

Save and except for the aforesaid changes of the Placing Price and the Long Stop Date under the Placing Agreement, all other terms of the Placing Agreement shall remain unchanged and the Placing Agreement (as revised and supplemented by the Second Supplemental Placing Agreement) shall remain in full force and effect. Accordingly, save and except for the changes made to the arrangement in connection with the Placing stipulated in this announcement, there are no further changes to the Placing.

Shareholders and potential investors should note that the Completion is subject to conditions under the Placing Agreement to be fulfilled. As the Placing may or may not proceed, Shareholders and potential investors are reminded to exercise caution when dealing in the Shares.

By Order of the Board
Huakang Biomedical Holdings Company Limited
Zhang Shuguang
Chairman and Executive Director

Hong Kong, 7 July 2022

As at the date of this announcement, the executive Directors are Mr. Zhang Shuguang, Mr. Zhang Chunguang, Mr. Poon Lai Yin Michael and Mr. He Jiaming; and the independent non-executive Directors are Dr. Chow Kwok Fai Joseph, Dr. Cheng Faat Ting Gary and Mr. Chan Kin Sang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the Stock Exchange website at www.hkexnews.hk for at least seven days from the date of publication and on the Company’s website at www.huakangbiomedical.com.